^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DZD1516

    i
    Other names: DZD1516, DZD-1516
    Company:
    Dizal Pharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    over1year
    Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor. (PubMed, Breast Cancer Res)
    DZD1516 provides positive proof of concept for an optimal HER2 inhibitor with high BBB penetration and HER2 selectivity. Further clinical evaluation of DZD1516 is warranted, with the RP2D being 250 mg BID.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    HER-2 positive • EGFR wild-type
    |
    DZD1516
    over2years
    DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Dizal Pharmaceuticals | Recruiting --> Active, not recruiting | N=94 --> 23
    Enrollment closed • Enrollment change • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • capecitabine • DZD1516
    4years
    DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=94, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • capecitabine • DZD1516
    over4years
    DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Dizal Pharmaceuticals
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • capecitabine • DZD1516